EVOLUS, INC. Proceeds from Convertible Debt
EVOLUS, INC. (EOLS) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2022-03-03
- EVOLUS, INC. proceeds from convertible debt for the quarter ending 2021-12-31 was $0.00.
- EVOLUS, INC. proceeds from convertible debt for the quarter ending 2020-12-31 was $0.00.
- EVOLUS, INC. proceeds from convertible debt for the quarter ending 2019-12-31 was $0.00.
- EVOLUS, INC. proceeds from convertible debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- EVOLUS, INC. proceeds from convertible debt for fiscal 2020 was $40.00M.
- EVOLUS, INC. proceeds from convertible debt for fiscal 2019 was $0.00.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 10-K · filed 2022-03-03 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-02 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $40.00M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $40.00M 10-Q · filed 2021-11-02 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |